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In this study, we investigated how thyroid hormone
(3,5,5-triiodo-L-thyronine, T3) inhibits binding of thy-
roid hormone receptor (TR) homodimers, but not TR-
retinoid X receptor heterodimers, to thyroid hormone
response elements. Specifically we asked why a small
subset of TR mutations that arise in resistance to thy-
roid hormone syndrome inhibit both T3 binding and
formation of TR homodimers on thyroid hormone re-
sponse elements. We reasoned that these mutations may
affect structural elements involved in the coupling of T3
binding to inhibition of TR DNA binding activity. Anal-
ysis of TR x-ray structures revealed that each of these
resistance to thyroid hormone syndrome mutations af-
fects a cluster of charged amino acids with potential for
ionic bond formation between oppositely charged part-
ners. Two clusters (1 and 2) are adjacent to the dimer
surface at the junction of helices 10 and 11. Targeted
mutagenesis of residues in Cluster 1 (Arg338, Lys342,
Asp351, and Asp355) and Cluster 2 (Arg429, Arg383, and
Glu311) confirmed that the clusters are required for sta-
ble T3 binding and for optimal TR homodimer formation
on DNA but also revealed that different arrangements of
charged residues are needed for these effects. We pro-
pose that the charge clusters are homodimer-specific
extensions of the dimer surface and further that T3 bind-
ing promotes specific rearrangements of these surfaces
that simultaneously block homodimer formation on
DNA and stabilize the bound hormone. Our data yield
insight into the way that T3 regulates TR DNA binding
activity and also highlight hitherto unsuspected T3-de-
pendent conformational changes in the receptor ligand
binding domain.
Thyroid hormone receptors (TR and TR)1 are conditional
transcription factors that play important roles in development,
metabolism, and homeostasis (1–4). TRs regulate gene tran-
scription in the presence of 3,5,3triiodo-L-thyronine (T3) and in
the absence of ligand (5). Current efforts to modulate TR ac-
tivities have focused on development of selective agonists that
mimic the beneficial effects of T3 upon circulating cholesterol
and body weight without producing unwanted effects of the
hormone on heart rate (6). However, there is also a need for TR
antagonists, which could represent improved and faster acting
treatments for hyperthyroidism and cardiac arrhythmias (6, 7).
Furthermore observations from TR/TR knock-out mice sug-
gest many clinical manifestations of hypothyroidism are due to
actions of unliganded TRs (8, 9). Thus, drugs that specifically
reverse actions of unliganded TRs could be useful for treating
hypothyroidism and would avoid risk of thyroid hormone ex-
cess (7). Improved understanding of unliganded TR structure
and ways that unliganded TRs rearrange in response to T3 will
facilitate development of all of these drugs.
Presently the organization of unliganded TR is only partly
understood (10, 11). X-ray structures of liganded TR C-termi-
nal ligand binding domains (LBDs) reveal a canonical -helical
structure with T3 buried in the core of the protein (12–16), but
there are no equivalent structures of unliganded TRs. It has
proven possible, however, to use a combination of x-ray struc-
tural information and targeted mutagenesis to learn about the
organization of unliganded TRs. For example, T3 blocks trans-
activation and transrepression activities of unliganded TRs by
promoting release of corepressors such as N-CoR and SMRT
(silencing mediator of retinoid and thyroid receptors) (5) and
induces a T3-dependent activation function (AF-2) that binds
coactivators such as the p160s (17). Functional analysis of TR
mutants reveals that AF-2 is comprised of surface-exposed
residues from helices (H) 3, 5, and 12 and that the corepressor
binding surface overlaps AF-2 but extends below the position of
H12 in the liganded state (18–21). Thus, it is possible to infer
that H12 is displaced in the unliganded state and that T3
binding leads to repositioning of H12 over the lower part of the
corepressor binding surface, simultaneously promoting core-
pressor release and completing the coactivator binding site (5).
T3 also regulates TR DNA binding activity (1). TRs utilize
their DNA binding domain to recognize specific thyroid hor-
mone response elements (TREs) comprised of AGGTCA repeats
and bind these elements either as heterodimers with the
closely related retinoid X receptor (RXR) or as homodimers and
monomers. T3 does not affect RXR-TR interactions with TREs
but does promote release of TR homodimers from some TREs
(inverted palindromes (F2/IP-6) and direct repeats (DR-4)) but
not from TREs at which TRs bind as monomers or paired
monomers (palindromes, TREpal) (22). TR homodimers bind
N-CoR more strongly than RXR-TR heterodimers (23, 24), and
the extent of TR homodimer binding to different TREs in vitro
correlates with the extent of repression from these elements in
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vivo (25, 26). Thus, it is thought that T3-dependent inhibition of
homodimer formation relieves transcriptional repression by
unliganded TRs. Nevertheless the mechanisms involved in cou-
pling of T3 binding to inhibition of DNA binding are not clear;
TRs utilize the same surface at the junction of H10 and H11 in
homodimer and heterodimer formation on DNA (27). The struc-
tural elements that render homodimers sensitive to T3 are
not known.
In this study, we utilized targeted mutagenesis to explore
elements of the TR that are specifically required for homodimer
formation on TREs and tested the hypothesis that the same
elements are involved in coupling T3 binding to inhibition of
DNA binding. Whereas most TR mutations that arise in re-
sistance to thyroid hormone syndrome (RTH) reduce the affin-
ity of TR for T3 (3, 28, 29), a small subset also inhibits binding
of TR homodimers, but not heterodimers, to TREs (30, 31).
Here we report that these RTH mutations affect clusters of
charged amino acids in the LBD with potential for electrostatic
stabilization of TR conformation but that distinct arrange-
ments of charged residues are needed for stable T3 binding and
DNA binding by unliganded TRs. We propose that the charge
clusters rearrange upon T3 binding to block homodimer forma-
tion and create new ionic bonds that stabilize bound hormone.
MATERIALS AND METHODS
TR Mutants—The pCMX vector was used for expression of the full-
length human TR (17). Mutations within TR-encoding sequences were
created using the QuikChange XL site-directed mutagenesis kit (Strat-
agene). Mutation of target sequences was verified by automated DNA
sequence (Elim Biopharmaceuticals, Inc., Hayward, CA).
Transfections—HeLa cells were maintained in Dulbecco’s modified
Eagle’s H-21 4.5 g/liter glucose medium containing 10% fetal bovine
serum, 2 mM glutamine, 50 units/ml penicillin, and 50 mg/ml strepto-
mycin. For transfection, cells were collected and resuspended in Dul-
becco’s phosphate-buffered saline (0.5 ml/4.5  107 cells) containing
0.1% dextrose and typically 4 g of reporter, 1 g of TR expression
vector or empty vector control, and 2 g of pCMV--galactosidase (17).
Cells were electroporated at 240 V and 960 microfarads, transferred to
fresh media, and plated into 12-well plates. After incubation for 24 h at
37 °C with T3 or vehicle, cells were collected, and pellets were lysed by
addition of 150 l of 100 mM Tris-HCl, pH 7.8, containing 0.1% Triton
X-100. The reporters contained two copies of each TRE (DR-4, F2, and
TREpal) upstream of the herpes simplex virus thymidine kinase pro-
moter TATA box linked to luciferase coding sequence. Luciferase and
-galactosidase activities were measured by using a luciferase assay
system (Promega) and Galacto-Light Plus -galactosidase reporter gene
assay system (Applied Biosystems).
Glutathione S-Transferase Pull-down Assays—Full-length human
TR was expressed in a coupled transcription translation system (TNT,
Promega). N-CoR (amino acids 1944–2453) and GRIP1 (amino acids
563–1121) were expressed in Escherichia coli strain BL21 as a fusion
protein with glutathione S-transferase according to the manufacturer’s
protocol (Amersham Biosciences). Bindings were performed by mixing
glutathione-linked Sepharose beads containing 4 g of glutathione S-
transferase fusion proteins (Coomassie Plus protein assay reagent,
Pierce) with 1–2 l of 35S-labeled human TR in 150 l of binding buffer
(20 mM HEPES, 150 mM KCl, 25 mM MgCl2, 10% glycerol, 1 mM dithi-
othreitol, 0.2 mM phenylmethylsulfonyl fluoride, and protease inhibi-
tors) containing 20 g/ml bovine serum albumin for 1.5 h. Beads were
washed three times with 200 l of binding buffer, the bound proteins
FIG. 1. Location of RTH mutations in charge clusters that are adjacent to the dimer surface. A, charge Clusters 1 and 2 are adjacent
to the TR dimer surface. The figure shows a space-filling model of the TR LBD. Residues in the dimerization surface (Leu400, Pro419, Leu422,
Met423, and Met430) are shown in green. Residues in Cluster 1 (Arg338, Lys342, Asp351, and Asp355) and Cluster 2 (Glu311, Arg383, and Arg429) are
shown in blue (positively charged) and red (negatively charged). B and C, closer view interactions between the residues that comprise charge
Clusters 1 (B) and 2 (C). Positively charged residues are shown in blue, and negatively charged residues are shown in red. Asterisk represents
residues mutated in RTH. D, alignment of Cluster 1 residues in TR and other NRs. E, alignment of Cluster 2 residues in TR and other NRs. hTR,
human TR; hRAR, human retinoic acid receptor; hLXR, human liver X receptor; hER, human estrogen receptor; hPXR, human pregnane X
receptor; hVDR, human vitamin D receptor; hCAR, human constitutive androstane receptor.
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were resuspended in SDS-PAGE loading buffer, and proteins were
separated using 10% SDS-polyacrylamide gel electrophoresis and visu-
alized by autoradiography.
T3 Binding Assay—TRs were expressed using the TNT T7 quick
coupled transcription translation system (Promega). The affinities of T3
binding were determined using a saturation binding assay. Briefly 15
fmol of each in vitro translated protein were incubated overnight at 4 °C
with varying concentrations of [125I]T3 (PerkinElmer Life Sciences) in
100 l of E400 buffer (400 mM NaCl, 20 mM KPO4, pH 8, 0.5 mM EDTA,
1.0 mM MgCl2, 10% glycerol), 1 mM monothioglycerol, and 50 g of calf
thymus histones (Calbiochem). The bound [125I]T3 was isolated by grav-
ity flow through a 2-ml Sephadex G-25 (Amersham Biosciences) column
and quantified using a -counter (COBRA, Packard Instruments). Off
rate (koff) was determined by adding a 1000-fold molar excess of unla-
beled T3 to a mixture containing TR and 1 nM [
125I]T3 incubated previ-
ously overnight at 4 °C; aliquots were taken at the indicated time points
to determine how rapidly the labeled ligand dissociates from TR. These
aliquots were applied to Sephadex G-25 columns, and TR-bound [125I]T3
was quantified using a -counter. As each T3-TR complex dissociates at
a random time, the amount of specific binding follows an exponential
dissociation equation: Y  Spanekx  Plateau where x is time (min),
Y is total binding (cpm), Span is the difference between binding at time
0 and plateau (cpm), and k is the dissociation rate constant (koff, ex-
pressed in min1). Binding curves were fit by nonlinear regression, and
dissociation constant (Kd) and koff values were calculated using the
one-site saturation binding, one-phase exponential decay, and one-
phase exponential association models, respectively, contained in the
Prism version 3.03 program (GraphPad Software, Inc., San Diego, CA).
Gel Shifts—Binding of TR to DNA was assayed by mixing 20 fmol of
TRs produced in a reticulocyte lysate system, TNT T7 (Promega), with
300,000 cpm [-32P]ATP-radiolabeled DR-4 and F2 oligonucleotides and
1 g of poly(dI-dC) (Amersham Biosciences) in a 20-l reaction (32). In
cases in which TR ligand binding activity was severely affected by
Cluster 1 mutations, the overall amount of translated TRs in the ex-
tracts was also verified independently by Western blot. The binding
buffer contained 25 mM HEPES, 50 mM KCl, 1 mM dithiothreitol, 10 M
ZnSO4, 0.1% Nonidet P-40, 5% glycerol. After 30 min at room temper-
ature, the mixture was loaded onto a 5% nondenaturing polyacrylamide
gel that was previously run for 30 min at 200 V. To visualize the
TR-DNA complexes, the gel was run at 4 °C for 120–180 min at 200 V
in a running buffer containing 45 mM Tris borate (pH 8.0) and 1 mM
EDTA. The gel was then fixed, dried, and exposed for autoradiography.
Statistical Analysis—All data are presented as means  S.D. One-
way ANOVA with Tukey’s post-test or t test was performed using
GraphPad Prism version 3.03 for Windows. Data analyzed referred to
at least three independent experiments. A p value of 0.05 was con-
sidered statistically significant.
RESULTS
RTH Mutations That Inhibit T3 and DNA Binding Reside in
Charge Clusters—RTH mutations that inhibit homodimer for-
mation on DNA affect positively charged Arg residues (R338W,
R429Q, and R316H) (30, 31, 33–35). In addition, we found that
another RTH mutation that affects a positively charged Lys
residue (K342I) also inhibits homodimer formation on DNA
(not shown). Investigation of TR structural models revealed
that each of these amino acids lies within separate clusters of
closely juxtaposed charged residues (Fig. 1A and Table I). The
TR LBD contains only one similar charge cluster that is not
known to be affected by RTHmutations (Cluster 4, see Table I).
Clusters 1 and 2 are comprised of residues that are exposed
or partially exposed on the surface of the LBD and are both
adjacent to the classical dimer surface at the junction of H10
and H11 (Fig. 1A and Table I). Unlike many residues that are
affected by RTH mutations, none of the residues in the clusters
directly contacts T3 or comprises part of a known coregulator
binding surface.
The residues in Clusters 1 and 2 have the potential to engage
in electrostatic interactions with each other. Cluster 1 includes
Arg338 and Lys342 on H7 and two negatively charged residues
on H8, Asp351 and Asp355, and is completely surface-exposed.
We originally suggested that Arg338 and Lys342 engage in par-
allel ionic pairings with Asp355 and Asp351, respectively, based
on analysis of x-ray crystal structures of the TR LBD (12).
Reinvestigation of TR-LBD structures (13) suggested another
arrangement: Arg338 and Lys342 both pair with Asp351, and
Asp355 is not directly engaged in the cluster (Fig. 1B). Cluster
2 includes Arg429 on H11 and Arg383 on H9, both of which are
also mutated in RTH but reported not to affect DNA binding
(36), and is partially surface-exposed. Here x-ray structures of
FIG. 2. Charge Cluster 1 mutations inhibit T3 activation. Max-
imal (Max.) activation and repression (A) and dose of T3 (B) required for
half-maximal activation at a T3-regulated reporter gene with an F2/IP-6
TRE. Activities obtained with TR mutants are compared with those
obtained with wild type TR, which is set to 100%. The EC50 T3
concentration for wild type TR was 15 nM for the F2 driven reporter.
In A, no statistical difference was found among mutants and wild type
(p  0.05). In B, different letters over bars indicate statistical difference
(p  0.05) according to ANOVA and Tukey’s test. WT or wt, wild type.
TABLE I
Location and conservation of TR charge clusters
RTH mutants known to inhibit DNA binding activity are shown in bold.
Cluster Residues Location RTH mutants Conservation
1 Arg338, Lys342,
Asp351, Asp355
Surface, links H7-H8 R338W, R338L,
K342I, A337del
Charged residues at similar
location in several NRs
2 Arg429, Arg383, Glu311 Partially buried, links
H11 and H10 to H6
R383H, R429Q Arg429 conserved in 70% of NRs
3 Arg316, Gln374,
Thr232, His229
Buried, links H6 and
H9 to H1
R316H Polar cluster observed in similar
location in many NRs
4 Arg410, His412,
Asp366, Glu369
Buried, links H9 and
H10-H11 loop
None Glu369 well conserved
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TR and TR indicated that both Arg residues pair with Glu311
on H6 in the LBD core (Fig. 1C).
Residues in Clusters 1 and 2 show considerable conservation.
They are conserved in TRs throughout vertebrate species (not
shown). Residues equivalent to those in charge Cluster 1 are
conserved on H7 and H8 in other NRs, including retinoic acid
receptors and PPARs (Fig. 1D). Residues in Cluster 2 show
even better conservation (Fig. 1E). Together all of these con-
siderations indicate that the charge clusters play an important,
and unappreciated, role in TR activities. Furthermore the fact
that mutations in the clusters affect T3 binding and homodimer
formation indicates that the clusters must play a role in activ-
ities associated with liganded and unliganded TRs.
Cluster 1 Is Required for Optimal T3 Binding—We first ex-
amined effects of mutations in Cluster 1 on activities of ligan-
ded TRs. Because residues of this cluster are completely sur-
face-exposed it appeared unlikely that these mutations would
exert indirect effects on TR function by disrupting internal
folding of the LBD. We introduced 1) Ala substitutions, which
swap a residue with a small neutral side chain for a residue
with a charged side chain and thereby eliminate the potential
for electrostatic interactions, and 2) charge reversal mutations,
which should disrupt ionic bonds between oppositely charged
residues by juxtaposing residues with like charges.
Fig. 2 shows effects of mutations on activity of transfected
TR in mammalian cells. TR Cluster 1 mutants did not affect
maximal activation of transcription from a TRE-driven re-
porter (F2) in the presence of saturating T3 or repression of
basal transcription in the absence of T3 (Fig. 2A). Nevertheless
several TR Cluster 1 mutants displayed altered T3 concentra-
tion dependence (Fig. 2B and Table II) both in HeLa cells
(shown here) and in other cells (U2-OS and CV-1, not shown).
Mutations in two residues (Arg338 and Asp351) led to reduced T3
sensitivity. The TRR338W RTHmutant required 17-fold more
T3 than wild type TR for half-maximal activation (EC50). TRs
bearing Ala substitutions at Arg338 and Asp351 (TRR338A and
TRD351A) exhibited more modest reductions in T3 sensitiv-
ity, and TRs with charge reversal mutations at Arg338 and
Asp351 (TRR338D and TRD351R) displayed more marked
reductions in T3 sensitivity. In contrast, different mutations at
Lys342 exhibited divergent effects. A relatively mild Ala substi-
tution mutation (TRK342A) had either no effect or slightly
enhanced T3 sensitivity (Table II). Nevertheless a more severe
charge reversal mutation, TRK342D, exhibited decreased T3
sensitivity as did the TRK342I RTH mutant (not shown).
Finally mutations at Asp355 did not reduce T3 sensitivity.
TRD355A and TRD355R either exhibited T3 sensitivity com-
FIG. 3. Effects of Cluster 1 mutations on activities of liganded TRs in vitro. A, mutations in Cluster 1 do not affect coregulator binding.
Shown are autoradiograms of SDS-polyacrylamide gels used to separate labeled TRs bound to bacterially expressed GRIP1 (amino acids 563–1121)
and N-CoR (amino acids 1944–2453) in pull-down assays. The result is representative of three experiments. B, Kd, equilibrium dissociation
constant. Mutants are compared with values obtained with wild type TR, which was 161.4  1012 M and set to 100%. Values represent the
averages of at least three determinations. C, kinetics of ligand dissociation from wild type and mutant TRs, koff. Values represent the averages of
at least three determinations. In B and C, different letters over bars indicate statistical difference (p  0.05) according to ANOVA and Tukey’s test.
WT or wt, wild type; GST, glutathione S-transferase.
TABLE II
Average EC50 for T3 response obtained with TRs bearing Cluster 1 mutants at different TREs
Values are compared to wild type TR set at 100%. Mean values S.D. are the average of at least three experiments. Different letters in the same
horizontal row indicate statistical difference (p 0.05), and different numbers in the same vertical column indicate statistical difference (p 0.05)
according to ANOVA and Tukey’s test.
TRE/TR TR R338A K342A D351A D355A
F2 (IP-6) 100a,1 357  149.1b,1 73  9.5a,1 608  185.5c,1 56  11.3a,1
DR-4 100a,1 112  14.6a,2 68  11.8a,1,2 389  98.6b,2 102  27.7a,2
TREpal 100a,b,1 155  37.0b,1,2 37  16.7a,2 308  56.7c,2 33  3.5a,1
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parable to wild type TR or enhanced T3 sensitivity at some
reporters (Fig. 2B and Table II).
None of the Cluster 1 mutations impaired binding to a coac-
tivator (GRIP1, Fig. 3A) or to a corepressor (N-CoR, Fig. 3A) in
pull-down assays in vitro. This is consistent with the results
that show no impairment in the maximal effect of the hormone
in transfection assays. By contrast, the same mutations that
reduced T3 sensitivity in vivo also reduced the affinity of the TR
for T3 (Fig. 3B) and increased T3 dissociation rates (Fig. 3C).
Together our results indicate that Arg338, Asp351, and, to a
lesser extent, Lys342 are required for optimal T3 binding and
response and that Asp355 is not. This is consistent with the
apparent organization of Cluster 1 in TR crystal structures
where Arg338, Lys342, and Asp351 side chains engage in elec-
trostatic interactions with each other, and Asp355 does not
(Fig. 1B).
Mutations in Cluster 1 Can Either Impair or Enhance Ho-
modimer Binding to DNA, and Effects Do Not Correlate with T3
Binding—Next we examined effects of mutations in Cluster 1
on TR homodimer formation on DNA. The data in Fig. 4A
confirmed that the TRR338W RTH mutant exhibits defective
homodimer formation at F2 and DR-4 elements along with
normal levels of heterodimer formation (30, 31). By contrast, an
artificial mutation (TRL422R) in the classical dimer interface
abolished both homodimer and heterodimer formation. In par-
allel, TRs bearing Ala substitution mutants at Arg338 and
Asp351 (both required for optimal T3 binding) exhibited reduced
homodimer but not heterodimer formation at F2 and DR-4
elements (Fig. 4B) just like the TRR338W RTH mutant. How-
ever, TRK342A displayed reduced homodimer formation even
though it did not inhibit T3 binding (compare Figs. 2B and 4B).
More surprisingly, the charge reversal mutants exhibited en-
hanced DNA binding (Fig. 4C) even though most of these mu-
tations inhibit T3 binding (Fig. 2B). The precise effect of the
charge reversal mutants varied; TRR338D showed enhanced
DNA binding in the absence of T3, whereas TRD351R and
TRK342D showed enhanced DNA binding in the presence or
absence of T3. TRD355R exhibited enhanced DNA binding in
the presence of T3, reversing the usual effects of T3 on TR DNA
binding activity (Fig. 4C). Again these effects were largely
homodimer-specific, although TRK342D did exhibit some-
what enhanced heterodimer formation. Together our results
confirm that Cluster 1 is required for TR homodimer but not
heterodimer formation on DNA. Nevertheless the same data
also revealed that different arrangements of charge are needed
for optimal DNA and T3 binding.
Charge Cluster 2 Residues Differentially Affect T3 Activation
and DNA Binding—Mutations in Cluster 2 (Arg383, Arg429, and
Glu311) also exhibited differential effects on activity of liganded
TRs and DNA binding. Fig. 5A shows that TRE311A exhibited
a much larger reduction in T3 sensitivity than TRs bearing
mutations at Arg429 and Arg383 (TRR429A and TRR383H)
(Fig. 5A). This finding is consistent with previous observations
that RTH mutations in these Arg residues only affect T3 sen-
sitivity weakly (30) and is also consistent with the organization
of Cluster 2 in TR structures (Fig. 1C); a mutation in Glu311
that breaks electrostatic interactions with both Arg residues
exhibited a more severe defect than mutations at Arg429 and
Arg383, which only break one bond. By contrast, TRE311A
(and TRR383H) bound to DNA as efficiently as wild type TRs
in the absence of T3, whereas TRR429A exhibited decreased
homodimer formation on DNA (Fig. 5B). Thus, Cluster 2 re-
quires different charged residues for optimal T3 response and
DNA binding just like Cluster 1.
FIG. 4. Mutations in charge Cluster 1 inhibit or enhance ho-
modimerization on DNA. A–C, autoradiograph of gel shift assays of
labeled F2 (A–C) and DR-4 (A and B) element oligonucleotides with wild
type TR (TRwt) and various TR mutants in the presence or absence of
both T3 and RXR. A, comparison of TR with TRR338W and a dimer
surface mutant (L422R). B, comparison of TR with Ala substitution
mutants as indicated. C, comparison of TR with charge reversal mu-
tants. WT, wild type; Retic., reticulocyte lysate.
FIG. 5. Mutations in Cluster 2 differentially affect T3 response
and DNA binding. A, Glu311 is required for optimal T3 response.
Shown is a summary of relative EC50 values for T3 response obtained in
transfections assays performed in HeLa cells with an F2-driven re-
porter gene as in Fig. 3. B, Arg429 is required for optimal homodimer
formation. Shown are electrophoretic mobility shift assays to determine
binding of Cluster 2 mutants to an F2 oligonucleotide as in Fig. 4. In A,
different letters over bars indicate statistical difference (p  0.05) ac-
cording to ANOVA and Tukey’s test. WT or wt, wild type.
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An Arg338-Asp351 Pair Stabilizes Bound T3—To learn how
individual residues within Cluster 1 interact, we examined
effects of multiple mutations in the cluster upon TR function.
First we reversed the positions of two residues that are most
important for optimal T3 binding, Arg
338 and Asp351. Fig. 6A
shows that TRR338D,D351R displayed markedly reduced T3
sensitivity in transfections like the R338D and D351R single
mutants. TRR338D,D351R also displayed decreased affinity
for T3 and increased dissociation rates of bound T3 with normal
levels of coregulator binding and TR homodimer formation on
DNA (not shown).
The phenotype of the TRR338D,D351R double mutant was
surprising; it is often possible to reverse the positions of resi-
dues in ionic pairs and regenerate wild type protein function.
Nevertheless Fig. 6B shows that introduction of Ala substitu-
tions at Lys342 and Asp355 restored the activity of the
TRR338D,D351R double mutant to near wild type levels but
not that of a TR mutant with like charges at both positions
(TRR338D,K342A,D355A). Thus, Arg338 and Asp351 can be
reversed without severe loss of TR function, suggesting that
they can form a reversible ionic bond that stabilizes liganded
TR. This effect can only be observed, however, when other
charges are removed from the cluster.
Cluster 1 Is Dispensable for Ligand TR Activity—Because
Lys342 and Asp355 interfere with TR activity and T3 binding
when the putative Arg338-Asp351 ionic bond is reversed (Fig. 6),
we asked whether Lys342 and Asp355 might also interfere with
TR activity and T3 binding in the context of wild type TR. To
do this, we examined effects of multiple Ala substitutions in
Cluster 1.
Mutations at Lys342 and Asp355 rescued effects of mutations
at Arg338 and Asp351. Fig. 7A shows that a TR double mutant
bearing Ala substitutions at residues that are required for
optimal T3 binding (TRR338A,D351A) displayed reduced T3
sensitivity and T3 binding and increased dissociation rates of
bound T3. Furthermore a TR double mutant bearing Ala sub-
stitutions at residues that are not required for optimal T3
binding (TRK342A,D355A) did not affect TR activity. These
results confirm that Arg338 and Asp351 are needed for optimal
hormone binding, and Lys342 and Asp355 are not. More surpris-
ingly, a double mutant that eliminated both positive charges in
Cluster 1 (TRR338A,K342A) exhibited a phenotype that was
similar to wild type TR. Furthermore a double mutant that
removed both negative charges (TRD351A,D355A) exhibited
a phenotype that was intermediate between TRD351A, re-
duced affinity for T3, and TRD355A, similar to wild type TR.
Thus, Ala substitution mutations at Lys342 and Asp355 rescue
effects of similar mutations at Arg338 and Asp351.
The fact that some mutations in Cluster 1 rescue effects of
others was underscored by the observation that elimination of
all charge within Cluster 1 with a quadruple Ala substitution
(TR4A) failed to inhibit T3 binding or liganded TR function.
TR4A displayed enhanced T3 sensitivity in transfections (Fig.
7B), slightly increased affinity for T3 (Table III), and normal
levels of coactivator and corepressor binding (not shown). Nev-
ertheless TR4A exhibited strongly reduced homodimer forma-
tion on DNA (Fig. 7C). This reduction in homodimer formation,
the largest obtained with any Cluster 1 mutation in this study
(not shown), was paralleled by impaired repression at a TR-
regulated reporter without T3 (Fig. 7B, inset).
Together our results show that, whereas two individual
residues in the cluster (Arg338 and Asp351) are required for
optimal T3 response and T3 binding, Cluster 1 itself is dis-
pensable for the function of liganded TR. Nevertheless Clus-
ter 1 is required for activities associated with unliganded
TRs: homodimer formation on DNA and transcriptional re-
pression (see “Discussion”).
DISCUSSION
In this study, we examined how TR DNA binding activity is
regulated by its LBD and by ligand. To begin to understand
this issue, we asked why some RTH mutations (R316H,
R338W, K342I, and R429Q) that reduce the affinity of TR for
T3 also inhibit binding of TR homodimers, but not het-
erodimers, to TREs (30, 31). We reasoned that these mutations
might affect structural elements that are involved in coupling
T3 binding to inhibition of DNA binding activity. We report
here that each of these RTH mutations affected amino acids
that lie within clusters of charged residues with potential for
electrostatic interactions between individual residues in the
cluster. Two of these clusters (1 and 2) are adjacent to the TR
dimer/heterodimer surface (Table I and Fig. 1). The importance
of the clusters is underscored by their conservation both in TRs
across evolution (not shown) and in other NRs (Fig. 1, D and E)
and by our studies, which revealed that mutations in Clusters
1 and 2 lead, variously, to increases and decreases in T3 bind-
ing and/or DNA binding.
The existence of functionally important clusters of charged
residues on the TR LBD surface was surprising because
proteins are largely stabilized by hydrophobic effects in
FIG. 6. Reversibility of the putative Arg338-Asp351 salt bridge.
A, Arg338 and Asp351 cannot be reversed without severe disruption of T3
response. Shown is a comparison of activities of wild type TR and
charge reversal mutants as a function of T3 concentration. Transfec-
tions were performed in HeLa cells with an F2-driven reporter. B,
Arg338 and Asp351 can be reversed in the absence of interfering charge
at Lys342 and Asp355. Ala substitution mutations at Lys342 and Asp355
restore activity of the TRR338D,D351R charge reversal mutant (D/R).
Data are presented as a comparison of EC50 values for different TR
mutants as in Fig. 3C. In B, different letters over bars indicate statis-
tical difference (p  0.05) according to ANOVA and Tukey’s test. wt,
wild type.
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which hydrophobic residues form the interior of the protein
and charged side chains are surface-exposed, freely solvated
with water (37). Nevertheless electrostatic interactions be-
tween oppositely charged side chains have been shown to
provide additional stability to proteins in several contexts,
including particular conformers of allosteric proteins, pro-
tein-protein interaction surfaces, and proteins in thermo-
philic organisms (37–40). For TRs, two RTH mutations that
disrupt ionic bonds, one in Cluster 3 (TRR316H) and a
single surface-exposed ionic bond between Arg243 in H3 and
Glu322 at the base of H6 (TRR243Q), lead to broadening of
experimental electron density in the lower part of the LBD in
x-ray structures (14, 15). This confirms that electrostatic
interactions between oppositely charged TR residues can
stabilize the liganded TR-LBD.
Our mutational analysis supports the notion that Clusters 1
and 2 are stabilizing elements for liganded TR. Mutations that
disrupted the predicted ionic bond arrangements in Clusters 1
and 2 led to reduced T3 sensitivity, reduced affinity for T3, and
increased T3 dissociation rates. These phenotypes resemble
those of aforementioned TR RTH mutations that destabilize
the TR LBD by breaking electrostatic interactions, R316H and
R243Q (14, 15). In addition, three lines of evidence indicate
that Arg338 and Asp351 form an ionic bond required for stable
T3 binding. 1) Placement of like, repelling charges at Arg
338
and Asp351 severely inhibited T3 binding (Fig. 2). 2) Arg
338 and
Asp351 could be reversed without significant disruption of T3
binding, albeit only in the absence of charge at Lys342 and
Asp355 (Fig. 6). 3) TRs with double mutations at Arg338 and
Asp351 exhibited phenotypes similar to single mutants, sug-
gesting that both residues are parts of the same structural
element (Figs. 6 and 7).
Nevertheless our results also suggest that the clusters adopt
a different organization in unliganded TRs. Distinct arrange-
ments of charge are required for optimal T3 binding and for
DNA binding by unliganded TR homodimers (Figs. 2–5). Thus,
the TRK342A mutation inhibited DNA but not T3 binding.
Furthermore and more strikingly, charge reversal mutations at
Arg338 (R338D), Asp351 (D351R), and Lys342 (K342D) all inhib-
ited T3 binding but not DNA binding, and a charge reversal
mutation at Asp355 (D355R) did not affect T3 binding yet en-
hanced TR homodimer formation on DNA in the presence of T3
(Fig. 4).
Other results are hard to reconcile with the simple notion
that Clusters 1 and 2 act as static stabilizing elements for
liganded and unliganded TRs. Cluster 1 was dispensable for
optimal T3 response and T3 binding (Fig. 7) even though Arg
338
and Asp351 were required for T3 binding (Figs. 2, 3, and 7).
Furthermore two Cluster 1 residues (Lys342 and Asp355) must
inhibit T3 binding to some extent as judged by the fact that
TRK342A and TRD355A mutants exhibited enhanced sen-
sitivity to T3 in transfections and increased affinity for T3 in
vitro and that Ala substitutions at both positions rescued ef-
fects of similar mutations at Arg338 and Asp351 (Fig. 7).
Our hypothesis to explain these observations is outlined in
Fig. 8. We propose that Clusters 1 and 2 are hormone-depend-
ent stabilizing elements for the TR LBD. We suggest that, in
the unliganded state, the clusters adopt an unspecified organi-
FIG. 7. Cluster 1 is dispensable for
liganded TR action. A, mutations at
Lys342 and Asp355 rescue effects of muta-
tions at Arg338 and Asp351. Shown is a
comparison of EC50, Kd, and koff values
obtained with TR mutants with single
and double Ala substitutions in Cluster 1;
data are presented as in Figs. 2 and 3. B,
Cluster 1 can be eliminated without loss
of function for liganded TR. Shown are
hormone activation profiles for human
TR wild type and a quadruple Ala mu-
tant (4xA) at an F2-TRE-regulated re-
porter. The data represent a single trans-
fection assay in which standard errors are
derived from multiple wells, representa-
tive of several experiments. The inset
shows maximal (Max.) activation and re-
pression obtained with TR and TR4A
(4xA). C, elimination of Cluster 1 inhibits
DNA binding. Shown is a gel shift com-
paring binding of TR and TR4A (4xAla)
on an F2-TRE. In A, different letters over
bars indicate statistical difference (p 
0.05) according to ANOVA and Tukey’s
test. WT or wt, wild type.
TABLE III
Charge Cluster 1 is dispensable for T3 binding
Means S.D. are the average of at least three experiments. The same
letters in the same column indicate no statistical difference (p  0.05)
according to t test.
Kd koff
1012 M 103 min1
TR 134.5  44.6a 2.32  0.72a
TR4A 67.1  23.6a 1.92  0.56a
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zation that is distinct from that observed in x-ray structures of
liganded TR LBDs but required for optimal homodimer for-
mation on DNA. Given the placement of these residues, we
favor the notion that the clusters comprise homodimer-specific
extensions of the dimer surface that engage in flexible contacts
with oppositely charged residues in partner LBDs or possibly
influence homodimer formation via distant stabilizing effects
on the dimer surface. We further suggest that T3 binding pro-
motes structural rearrangements in the TR LBD that reposi-
tion the charged residues, simultaneously breaking the inter-
actions that are needed for optimal homodimer formation on
DNA and creating new ionic bonds that hold the walls of the
hormone binding pocket in an appropriate configuration for
stable T3 interactions.
Our model suggests explanations for several apparently par-
adoxical results. 1) Different charge arrangements are required
for T3 binding and homodimer formation on TREs because the
clusters adopt different organizations in the presence and ab-
sence of T3. 2) Cluster 1 could be eliminated without obvious
effect on TR even though mutations in Arg338 and Asp351
inhibit T3 binding because the Arg
338-Asp351 ionic bond coun-
teracts the tendency of the Cluster 1 to revert toward the
organization in the unliganded state. If Cluster 1 is eliminated,
the requirement for the stabilizing element is eliminated. 3)
Lys342 and Asp355 inhibited T3 binding because they stabilize
the unliganded TR conformer that binds to DNA as a ho-
modimer but only provide limited stability (Lys342) or no addi-
tional stability (Asp355) to the liganded TR conformer. Here
mutation of Lys342 and Asp355 enhanced T3 response and T3
binding by counteracting the tendency of the cluster to revert to
its organization in unliganded state.
We recognize that our model cannot yet be verified directly
because apoTR dimer structures are not available. Neverthe-
less analysis of liganded and unliganded RXR crystal struc-
tures revealed evidence that is consistent with the basic pre-
dictions of our model. First charged residues in the region of
RXR that is equivalent to H8 rearrange in response to ligand
binding (Fig. 9). RXR Glu352 and Lys356 form an ionic bond
within the interior of the unliganded LBD. Binding of 9-cis-
retinoic acid twists the helix, exposing the charged side chains
on the protein surface where they can pair with PPARs in
RXR-PPAR heterodimers (41–45). We suggest that TR charge
clusters (on H7, H8, and H11) must undergo similar ligand-de-
pendent rearrangements. This model implies that functionally
important conformational rearrangements that accompany T3
binding are not restricted to H12 and that T3 induces reorga-
nization of the opposite face of the TR near the dimer surface.
Finally our results also lend support to the notion that TR
homodimers are highly active in mediating transcriptional re-
pression in vivo (25, 26). We observed that a TR mutant that
strongly inhibited homodimer formation on TREs (TR4A) im-
paired the ability of unliganded TRs to suppress transcription
in the absence of hormone (Fig. 7B). We predict that mutations
such as those described here that either specifically inhibit or
stabilize particular oligomeric forms of TR will help us to fur-
ther dissect the relative roles of RXR-TR heterodimers and TR
homodimers in vivo.
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